We recently isolated a cDNA clone for the human cholecystokinin (CCK)
B/gastrin receptor and permanently expressed this receptor cDNA in NIH-3T3 cells. [
125I]CCK-8 specifically bound to the membrane of the transfectant, and this binding was displaced by unlabeled CCK-8 with an IC
50 of 0.32 nM. Treatment of these cells with CCK-8 increased the intracellular Ca
2+ concentration with an EC
50 of 0.30 nM. Using these cells expressing functional human CCK
B/gastrin receptors, we investigated the pharmacological properties of (
R)-1-[2, 3-dihydro-l-(2''-methylphenacyl)-2-oxo-5-phenyl-1
H-1, 4-benzodiazepin-3-yl]-3-(3-methylphenyl) urea (YM022), a potent and selective CCK
B/gastrin receptor antagonist in rats. YM022 potently inhibited [
125I] CCK-8 binding to the membrane with an IC
50 of 55 pM and CCK-8-induced Ca
2+ mobilization with that of 7.4 nM. On the other hand, its racemate and enantiomer more weakly inhibited this binding (IC
50 of 110 pM and 11 nM, respectively) and Ca
2+ mobilization (IC
50 of 18 nM and 94 nM, respectively). These results indicate that YM022 stereoselectively recognizes the human CCK
B/gastrin receptor as a potent antagonist and that the established transfectant is useful for characterization of human CCK
B/gastrin-receptor ligands.
View full abstract